Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

OBJECTIVES: This study aimed to explore the novel biomarkers for immune checkpoint inhibitor (ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and expression of programmed death receptor 1 ligand (PD‐L1). MATERIALS AND METHODS: Tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yunfei, Lei, Youming, Liu, Li, Zhang, Shiyue, Wang, Wenjing, Zhao, Juan, Zhao, Songhui, Dong, Xiaowei, Yao, Ming, Wang, Kai, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982619/
https://www.ncbi.nlm.nih.gov/pubmed/33655698
http://dx.doi.org/10.1002/cam4.3649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982619/
https://www.ncbi.nlm.nih.gov/pubmed/33655698
http://dx.doi.org/10.1002/cam4.3649

Ejemplares similares